Trial Profile
Open-label Single-arm PD and PK Study of Landiolol in Patients with Tachycardic Atrial Fibrillation or Atrial Flutter
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2019
Price :
$35
*
At a glance
- Drugs Landiolol (Primary)
- Indications Atrial fibrillation; Atrial flutter
- Focus Therapeutic Use
- Sponsors AOP Orphan Pharmaceuticals AG
- 06 Dec 2019 Results published in the Circulation Journal
- 24 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 11 Nov 2014 New trial record